PCV31 - Estimated Budget Impact Of Cholesterol Decreasing In The Russian Population

Abstract

Budget impact evaluation of cholesterol level decreasing in the Russian population of patients with Cardio Vascular Diseases (CVD). Population attributive risk of hypercholesterolemia (HCE) was used for evaluation of the share of CVD incidence/mortality/costs, based on official statistics and epidemiological data. Total economic burden was estimated regarding direct (medical and non-medical) and indirect costs. Social and economic effectiveness of (Choletesterol-LDL) СS-LDL decrease by 1 mmol/l among patients with СVD, including health care system economy and reduction of economic losses were estimated, taking into account primary/recurring PCI. GDP losses due to premature mortality in economically active age from diseases associated with HCE with the lack of lipid lowering treatment (or without it) is expected as $505 bln for ischemic cardiac disease and $303 bln. for other circulatory illnesses annually. Lowering effect of CS-LDL by 1 mmol/l (during a year) is: outpatient care cost can decrease more than in 3 times for Ischemic Cardiac Disease (IHD) and in 5 times for Stroke that lead to decrease of budget impact in 3,8 and 5,0 times accordingly. Hospital admission is expected to be in 4,5-5 times less. Under the current rate of performing of PCI, the reduction of CS-LDL by 1 mmol/l enables to reduce the number of PCI by 20% annually. It will reduce the annual expenditures on this kind of treatment by almost 5 times or ~$113 mln annually). Decrease CS-LDL by 1 mmol/l can save ~$1,59 bln. due to less myocardial infarction, ~$1,32 bln. for strokes. On a national level the decrease of expenditures and losses in the economy which are analysed will make up ~$9,65 bln. (~0,7% of GDP). Decrease of CS-LDL for patients with CVD has economic effect on health care system and can lead to decrease of budget impact and has social humanitarian effects.